



Published on *SWOT Analysis* (<https://www.swotanalysis.info>)

Home > Global and China Infliximab and Biosimilar Market Insights, Forecast to 2026

Global and China Infliximab and Biosimilar Market Insights, Forecast to 2026

Publication ID:

QYR11201064

Publication Date:

November 23, 2020

Pages:

127

Publisher:

QYR

Region:

Global [1]

\$3,900.00

Publication License Type *

Single User License (PDF), \$3,900.00

Global License (PDF), \$7,800.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Infliximab and Biosimilar market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Infliximab and Biosimilar

market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Infliximab and Biosimilar market is segmented into

Infliximab

Infliximab-dyyb

Infliximab-abda

Segment by Application, the Infliximab and Biosimilar market is segmented into

Crohn's Disease

Pediatric Crohn's Disease

Ulcerative Colitis

Rheumatoid Arthritis

Ankylosing Spondylitis

Psoriatic Arthritis

Plaque Psoriasis

Regional and Country-level Analysis

The Infliximab and Biosimilar market is analysed and market size information is provided by regions (countries).

The key regions covered in the Infliximab and Biosimilar market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Infliximab and Biosimilar Market Share Analysis

Infliximab and Biosimilar market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Infliximab and Biosimilar business, the date to enter into the Infliximab and Biosimilar market, Infliximab and Biosimilar product introduction, recent developments, etc.

The major vendors covered:

Janssen Biotech

Merck and Co.

Pfizer

...

Table Of Contents:

1 Study Coverage

1.1 Infiximab and Biosimilar Product Introduction

1.2 Market Segments

1.3 Key Infiximab and Biosimilar Manufacturers Covered: Ranking by Revenue

1.4 Market by Type

1.4.1 Global Infiximab and Biosimilar Market Size Growth Rate by Type

1.4.2 Infiximab

1.4.3 Infiximab-dyyb

1.4.4 Infiximab-abda

1.5 Market by Application

1.5.1 Global Infiximab and Biosimilar Market Size Growth Rate by Application

1.5.2 Crohn's Disease

1.5.3 Pediatric Crohn's Disease

1.5.4 Ulcerative Colitis

1.5.5 Rheumatoid Arthritis

1.5.6 Ankylosing Spondylitis

1.5.7 Psoriatic Arthritis

1.5.8 Plaque Psoriasis

1.6 Study Objectives

1.7 Years Considered

2 Executive Summary

2.1 Global Infiximab and Biosimilar Market Size, Estimates and Forecasts

2.1.1 Global Infiximab and Biosimilar Revenue 2015-2026

2.1.2 Global Infiximab and Biosimilar Sales 2015-2026

2.2 Global Infiximab and Biosimilar, Market Size by Producing Regions: 2015 VS 2020 VS 2026

2.3 Infiximab and Biosimilar Historical Market Size by Region (2015-2020)

2.3.1 Global Infiximab and Biosimilar Retrospective Market Scenario in Sales by Region: 2015-2020

2.3.2 Global Infiximab and Biosimilar Retrospective Market Scenario in Revenue by Region: 2015-2020

2.4 Infiximab and Biosimilar Market Estimates and Projections by Region (2021-2026)

2.4.1 Global Infiximab and Biosimilar Sales Forecast by Region (2021-2026)

2.4.2 Global Infiximab and Biosimilar Revenue Forecast by Region (2021-2026)

3 Global Infiximab and Biosimilar Competitor Landscape by Players

3.1 Global Top Infiximab and Biosimilar Sales by Manufacturers

3.1.1 Global Infiximab and Biosimilar Sales by Manufacturers (2015-2020)

3.1.2 Global Infiximab and Biosimilar Sales Market Share by Manufacturers (2015-2020)

3.2 Global Infiximab and Biosimilar Manufacturers by Revenue

3.2.1 Global Infiximab and Biosimilar Revenue by Manufacturers (2015-2020)

- 3.2.2 Global Infiximab and Biosimilar Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Infiximab and Biosimilar Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Infiximab and Biosimilar Revenue in 2019
- 3.2.5 Global Infiximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Global Infiximab and Biosimilar Price by Manufacturers
- 3.4 Global Infiximab and Biosimilar Manufacturing Base Distribution, Product Types
 - 3.4.1 Infiximab and Biosimilar Manufacturers Manufacturing Base Distribution, Headquarters
 - 3.4.2 Manufacturers Infiximab and Biosimilar Product Type
 - 3.4.3 Date of International Manufacturers Enter into Infiximab and Biosimilar Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
- 4 Market Size by Type (2015-2026)
 - 4.1 Global Infiximab and Biosimilar Market Size by Type (2015-2020)
 - 4.1.1 Global Infiximab and Biosimilar Sales by Type (2015-2020)
 - 4.1.2 Global Infiximab and Biosimilar Revenue by Type (2015-2020)
 - 4.1.3 Infiximab and Biosimilar Average Selling Price (ASP) by Type (2015-2026)
 - 4.2 Global Infiximab and Biosimilar Market Size Forecast by Type (2021-2026)
 - 4.2.1 Global Infiximab and Biosimilar Sales Forecast by Type (2021-2026)
 - 4.2.2 Global Infiximab and Biosimilar Revenue Forecast by Type (2021-2026)
 - 4.2.3 Infiximab and Biosimilar Average Selling Price (ASP) Forecast by Type (2021-2026)
 - 4.3 Global Infiximab and Biosimilar Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
- 5 Market Size by Application (2015-2026)
 - 5.1 Global Infiximab and Biosimilar Market Size by Application (2015-2020)
 - 5.1.1 Global Infiximab and Biosimilar Sales by Application (2015-2020)
 - 5.1.2 Global Infiximab and Biosimilar Revenue by Application (2015-2020)
 - 5.1.3 Infiximab and Biosimilar Price by Application (2015-2020)
 - 5.2 Infiximab and Biosimilar Market Size Forecast by Application (2021-2026)
 - 5.2.1 Global Infiximab and Biosimilar Sales Forecast by Application (2021-2026)
 - 5.2.2 Global Infiximab and Biosimilar Revenue Forecast by Application (2021-2026)
 - 5.2.3 Global Infiximab and Biosimilar Price Forecast by Application (2021-2026)
- 6 China by Players, Type and Application
 - 6.1 China Infiximab and Biosimilar Market Size YoY Growth 2015-2026
 - 6.1.1 China Infiximab and Biosimilar Sales YoY Growth 2015-2026
 - 6.1.2 China Infiximab and Biosimilar Revenue YoY Growth 2015-2026
 - 6.1.3 China Infiximab and Biosimilar Market Share in Global Market 2015-2026
 - 6.2 China Infiximab and Biosimilar Market Size by Players (International and Local Players)
 - 6.2.1 China Top Infiximab and Biosimilar Players by Sales (2015-2020)
 - 6.2.2 China Top Infiximab and Biosimilar Players by Revenue (2015-2020)

- 6.3 China Infliximab and Biosimilar Historic Market Review by Type (2015-2020)
 - 6.3.1 China Infliximab and Biosimilar Sales Market Share by Type (2015-2020)
 - 6.3.2 China Infliximab and Biosimilar Revenue Market Share by Type (2015-2020)
 - 6.3.3 China Infliximab and Biosimilar Price by Type (2015-2020)
- 6.4 China Infliximab and Biosimilar Market Estimates and Forecasts by Type (2021-2026)
 - 6.4.1 China Infliximab and Biosimilar Sales Forecast by Type (2021-2026)
 - 6.4.2 China Infliximab and Biosimilar Revenue Forecast by Type (2021-2026)
 - 6.4.3 China Infliximab and Biosimilar Price Forecast by Type (2021-2026)
- 6.5 China Infliximab and Biosimilar Historic Market Review by Application (2015-2020)
 - 6.5.1 China Infliximab and Biosimilar Sales Market Share by Application (2015-2020)
 - 6.5.2 China Infliximab and Biosimilar Revenue Market Share by Application (2015-2020)
 - 6.5.3 China Infliximab and Biosimilar Price by Application (2015-2020)
- 6.6 China Infliximab and Biosimilar Market Estimates and Forecasts by Application (2021-2026)
 - 6.6.1 China Infliximab and Biosimilar Sales Forecast by Application (2021-2026)
 - 6.6.2 China Infliximab and Biosimilar Revenue Forecast by Application (2021-2026)
 - 6.6.3 China Infliximab and Biosimilar Price Forecast by Application (2021-2026)

7 North America

- 7.1 North America Infliximab and Biosimilar Market Size YoY Growth 2015-2026
- 7.2 North America Infliximab and Biosimilar Market Facts & Figures by Country
 - 7.2.1 North America Infliximab and Biosimilar Sales by Country (2015-2020)
 - 7.2.2 North America Infliximab and Biosimilar Revenue by Country (2015-2020)
 - 7.2.3 U.S.
 - 7.2.4 Canada

8 Europe

- 8.1 Europe Infliximab and Biosimilar Market Size YoY Growth 2015-2026
- 8.2 Europe Infliximab and Biosimilar Market Facts & Figures by Country
 - 8.2.1 Europe Infliximab and Biosimilar Sales by Country
 - 8.2.2 Europe Infliximab and Biosimilar Revenue by Country
 - 8.2.3 Germany
 - 8.2.4 France
 - 8.2.5 U.K.
 - 8.2.6 Italy
 - 8.2.7 Russia

9 Asia Pacific

- 9.1 Asia Pacific Infliximab and Biosimilar Market Size YoY Growth 2015-2026
- 9.2 Asia Pacific Infliximab and Biosimilar Market Facts & Figures by Country
 - 9.2.1 Asia Pacific Infliximab and Biosimilar Sales by Region (2015-2020)
 - 9.2.2 Asia Pacific Infliximab and Biosimilar Revenue by Region

- 12.2.4 Merck and Co. Infliximab and Biosimilar Products Offered
- 12.2.5 Merck and Co. Recent Development
- 12.3 Pfizer
 - 12.3.1 Pfizer Corporation Information
 - 12.3.2 Pfizer Description and Business Overview
 - 12.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
 - 12.3.4 Pfizer Infliximab and Biosimilar Products Offered
 - 12.3.5 Pfizer Recent Development
- 12.11 Janssen Biotech
 - 12.11.1 Janssen Biotech Corporation Information
 - 12.11.2 Janssen Biotech Description and Business Overview
 - 12.11.3 Janssen Biotech Sales, Revenue and Gross Margin (2015-2020)
 - 12.11.4 Janssen Biotech Infliximab and Biosimilar Products Offered
 - 12.11.5 Janssen Biotech Recent Development
- 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
 - 13.1 Market Opportunities and Drivers
 - 13.2 Market Challenges
 - 13.3 Market Risks/Restraints
 - 13.4 Porter's Five Forces Analysis
 - 13.5 Primary Interviews with Key Infliximab and Biosimilar Players (Opinion Leaders)
- 14 Value Chain and Sales Channels Analysis
 - 14.1 Value Chain Analysis
 - 14.2 Infliximab and Biosimilar Customers
 - 14.3 Sales Channels Analysis
 - 14.3.1 Sales Channels
 - 14.3.2 Distributors
- 15 Research Findings and Conclusion
- 16 Appendix
 - 16.1 Research Methodology
 - 16.1.1 Methodology/Research Approach
 - 16.1.2 Data Source
 - 16.2 Author Details
 - 16.3 Disclaimer

Companies Mentioned:

Janssen Biotech
Merck and Co.
Pfizer

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

[What is SWOT Analysis?](#)

March 12

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

Source URL:<https://www.swotanalysis.info/qyr/global-and-china-infliximab-and-biosimilar-market-insights-forecast-2026>

Links

[1] <https://www.swotanalysis.info/region/global>